"ALN-TTR02-011, APOLLO-B: A Phase 3, Randomized,
Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of
Patisiran in Patients with Transthyretin Amyloidosis with Car
09/12/2019 - 09/12/2024 (PI)Alnylam Pharmaceuticals, Inc.
ALN-TTRSC02, HELIOS-B: A Phase 3, Randomized, Double blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cara
12/04/2019 - 12/04/2022 (PI)Alnylam Pharmaceuticals, Inc.
Protocol # ION-682844-CS3: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
11/15/2019 - 11/15/2022 (Subcontract PI)Pharmaceutical Research Associates, Inc. IonisPharmaceuticals
"A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy"
10/04/2019 - 10/04/2022 (PI)Eidos Therapeutics, Inc.
An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects with Leptomeningeal TTR Amyloidosis (ATTR) with and without CNS…
09/14/2018 - 08/12/2022 (PI)Corino Therapeutics
HELIOS-A: A Phase 3 Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with hATTR Amyloidosis
03/28/2019 - 03/27/2022 (PI)Alnylam Pharmaceuticals, Inc.
A study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
03/27/2019 - 03/26/2022 (Co-PI)
PI: Andrea Havasi, MDAlnylam Pharmaceuticals, Inc.
Expanded Access Protocol of Patisiran for Patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polynenropathy
10/31/2016 - 10/30/2021 (PI)Alnylam Pharmaceuticals, Inc.
Protocol #ISIS 420915-CS4, A Non-Interventional Study to Monitor the Survival Status of Patients That Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3
05/14/2018 - 05/13/2021 (PI)Ionis Pharmaceuticals, Inc.
Protocol #CS5 - Expanded Access Program for Inotersen (ISIS 420915) in Patients with Hereditary Transthyretin Amyloidosis (hATTR)
04/17/2018 - 04/16/2021 (PI)Ionis Pharmaceuticals, Inc.
Showing 10 of 28 results.
Show All Results